Fore fires CEO Malik after SEC insider trading charges during his time as Immunomedics CFO

The U.S. Securities and Exchange Commission (SEC) charged Usama Malik with insider trading during his time as chief financial officer of Immunomedics, a biopharma he helped lead to a $21 billion exit via a Gilead Sciences acquisition last year.